It has been reported that long chain acyl carnitine accumulates in ischemic myocardium, and L-carnitine prevents ventricular arrhythmias as well as the accumulation of long chain acyl carnitine in ischemic and free fatty acid supplemented hearts. The purpose of this study was to observe the electrophysiological effects of long chain acyl carnitine, and to evaluate the protective effect of L-carnitine on the transmembrane action potential impaired by long chain acyl carnitine. Using standard microelectrode techniques, transmembrane action potentials were recorded from isolated canine papillary muscle.
H IGH concentration of free fatty acids (FFA) have been reported to provoke malignant dysrhythmias in ischemic heart disease1) and in experimental animals.2),3) Recent studies have reported that FFA cause a concentration-dependent decrease in the action potential duration and a corresponding shortening of effective refractory period.4)-6) Several explanations have been proposed, such as a nonspecific detergent action on biomembranes,7) uncoupling of oxidative phosphorylation,8),9) inhibition of enzymes,10) and interference with glycolytically derived ATP in the cytoplasm.11), 12) Recently, much attention has been focused on the accumulation of long chain acyl CoA and long chain acyl carnitine (metabolites in FFA oxidation), as a cause of the toxic cardiac effects of myocardial ischemia and excess FFA.13)-15) Furthermore, protective effects of exogenous L-carnitine have been demonstrated in animals with acute myocardial ischemia and supplemental excess FFA.16)-19) The purpose of this study was to observe the electrophysiological effects of long chain acyl carnitine, and to evaluate the protective effect of L-carnitine on transmembrane action potentials impaired by long chain acyl carnitine.
METHODS
Mongrel dogs weighing 8-12Kg were anesthetized with sodium pentobarbital (30mg/Kg, iv). The hearts were removed and immediately placed in cooled and oxygenated Tyrode's solution. A small sample of papillary muscle was rapidly excised from the right ventricle and placed in a tissue bath. The bath was perfused with Tyrode's solution, oxygenated with 95% oxygen and 5% carbon dioxide, at a constant rate of 7ml/min. The pH of the solution was maintained at 7.4, and the composition of the solution was as follows (in mM): NaCI, 137; NaHCO3, 12; dextrose, 5.5; KCl, 3.0; CaCl2, 2.7; NaH2PO4, 1.8; and MgCl2, 0.5. The papillary muscle was stimulated through a bipolar Teflon-coated silver electrode placed on the papillary muscle at one end of the preparation, at twice the diastolic threshold in intensity with rectangular pulses of 2.0msec duration. The basic cycle length was 1sec. Transmembrane action potentials were recorded from the papillary muscle through machine-pulled glass microelectrodes filled with 3M KCl and with tip resistances of 10 to 15 megohms. The following parameters of the transmembrane action potential were measured: resting membrane potential (RMP), action potential amplitude (APA), and duration of action potential from the upstroke to 20, 50, and 90% repolarization (APD20, APD50, APD90). The effective refractory period (ERP) was determined by applying a test pulse at a desired coupling interval in every eighth cycle of driving pulses. Stimulating pulses were 2msec in duration and 4 times the diastolic threshold in intensity. The maximum upstroke velocity of phase 0 (dV/dTmax) was obtained by electronic differentiation and displayed on an oscilloscope. After performing the control measurements, the preparations were perfused with the Tyrode's solution containing either 0.3mM or 0.6mM palmitoyl carnitine and a mixture of palmitoyl carnitine (0.3mM) and L-carnitine (25mM). Effects of the agents were examined 30min after starting the perfusion. Statistical analysis was performed using Student's t test and the significance was established at p<0.05. is summarized in Table I . A significant decrease in RMP, APA and dV/ dTmax was observed at a concentration of 0.3mM. Palmitoyl carnitine at a concentration of 0.6mM caused a further decrease in RMP, APA, and dV/ dTmax. Both the APD at all measured levels of repolarization and ERP shortened significantly at a concentration of 0.3mM. Palmitoyl carnitine at a concentration of 0.6mM further shortened the APD, but there was no significant change in ERP. Action potentials in a representative case are shown in Fig. 1 . Effect of L-carnitine on transmembrane action potential impaired by palmitoyl carnitine Effect of L-carnitine on transmembrane action potentials impaired by palmitoyl carnitine was examined. Canine papillary muscle was perfused with Tyrode's solution containing palmitoyl carnitine (0.3mM) or a mixture of palmitoyl carnitine (0.3mM) and L-carnitine (25mM). Table II summarizes the effects of the lower dose of palmitoyl carnitine and the mixture of (1) control, (2) palmitoyl carnitine (0.3mM), (3) palmitoyl carnitine (0.3mM) and L-carnitine (25mM).
Potentials Impaired
by Palmitoyl Carnitine and L-carnitine (25mM) by a non-paired t-test. Abbreviations are the same as in Table I. palmitoyl carnitine and L-carnitine on action potentials. L-carnitine prevented the decrease in dV/dTmax, and the shortening of APD50, APD90, and ERP caused by palmitoyl carnitine. As shown in Fig. 2 , L-carnitine prevented the effect of palmitoyl carnitine on transmembrane action potentials.
DISCUSSION
In this study, application of palmitoyl carnitine, an endogenous long chain acyl carnitine, causes appreciable changes in transmembrane action potentials of canine papillary muscle. RMP, APA, and dV/dTmax were decreased in a concentration-dependent manner, and APD and ERP were shortened. Although ionic alterations were not delineated in this study, the APD shortening evoked by palmitoyl carnitine was most prominent at 20% and 50% of full repolarization, which may result partly from the attenuation of slow inward current during the plateau.20) The reduction in APD by Jpn 
